Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.76 |
| ▸ | FAAH | O00519 | 6/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.73 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | XBP1 | P17861 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.73 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495341 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL6723806 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL29064617 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL155748 | 0.87 | MGLL (1.00) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL20351983 | 0.85 | MGLL (1.00) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL5383694 | 0.85 | MGLL (1.00) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL13815841 | 0.85 | MGLL (1.00) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL818349 | 0.85 | MGLL (1.00) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL549065 | 0.85 | MGLL (1.00) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL258626 | 0.85 | MGLL (1.00) | MGLLFAAHALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | claimed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | claimed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | claimed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | claimed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20090118471-A1 | NOVEL COUMARIN DERIVATIVES | THE UNIVERSITY OF TOKYO (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7482473-B2 | Coumarin derivative | THE UNIVERSITY OF TOKYO (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20070197778-A1 | NOVEL COUMARIN DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118471-A1 | NOVEL COUMARIN DERIVATIVES | CBR3, MRPS23, MRPS22 | MGLL 4760/4885FAAH 3770/4885ALDH1A1 365/4885 |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | MGLL 707/4885FAAH 1228/4885ALDH1A1 4114/4885 |
| US-20070197778-A1 | NOVEL COUMARIN DERIVATIVE | CBR3, MRPS22, MRPS23 | MGLL 4769/4885FAAH 3817/4885ALDH1A1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.